Online dissolution of Metformin ER tablets using Electrolab Veritas-08 with Shimadzu Nexera FV

Significance of the Topic

Automation in dissolution testing for extended release (ER) formulations ensures reliable profiling of drug release over prolonged periods, minimizes manual errors, and upholds regulatory compliance. Accurate assessment of ER tablets is essential to confirm therapeutic efficacy and patient safety over the intended dosage interval.

Study Objectives and Overview

This work illustrates a fully automated online dissolution–HPLC system for metformin ER tablets, integrating an Electrolab Veritas-08 dissolution tester with a Shimadzu Nexera FV UHPLC. Objectives:

• Implement continuous, unattended sampling and analysis
• Maintain full traceability and audit trail throughout the process
• Generate dissolution profiles up to 720 minutes in real time

Methodology and Instrumentation

The automated workflow was configured as follows:

• Apparatus: USP Type II (paddle) at 37 °C, 100 rpm
• Dissolution medium: 1000 mL phosphate buffer pH 6.8
• Sampling time points: 5, 10, 15, 20, 25, 30, 60, 120, 240, 360, 480, 600, 720 min
• Automated system: Electrolab Veritas-08 connected to Shimadzu Nexera FV
• Software: LabSolutions for unified control, logging, and reporting
• Chromatography: Shiseido C18 column (4.6 × 150 mm, 5 µm), 45 °C, flow rate 0.75 mL/min, detection at 218 nm
• Online sample handling: 3-stage filtration, 10× dilution in the autosampler at 4 °C

Results and Discussion

Automated sampling produced consistent chromatograms at both early (5 min) and late (240 min) intervals. System suitability tests demonstrated high precision (retention time RSD < 0.04 %, peak area RSD < 1 %). Dissolution data across six vessels met the USP criterion of ≥ 80 % release by 600 min, with overall variability below 7 %.

Benefits and Practical Applications

• Walk-away operation reduces labor and human intervention
• Comprehensive audit trail and data integrity support regulatory compliance
• High sampling frequency enhances resolution of release profiles
• Scalable approach for various ER dosage forms in QA/QC and R&D settings

Future Trends and Potential Applications

Integration with inline spectroscopic detectors, real-time process analytical technology (PAT), miniaturized flow circuits, and AI-driven data analysis will further streamline method development and quality control, enabling predictive dissolution modeling and adaptive testing strategies.

Conclusion

The combined Veritas-08/Nexera FV platform delivers a robust, fully automated solution for dissolution testing of ER tablets, achieving reliable high-resolution release profiles with minimal manual input. This integrated workflow enhances laboratory productivity, data quality, and compliance in pharmaceutical analysis.